8-K: Palatin Inks $300M+ Retinal Disease Deal with BI

Palatin Technologies has entered a global research collaboration and licensing agreement with Boehringer Ingelheim for melanocortin receptor-targeted peptides to treat retinal diseases, including diabetic retinopathy.

Summary

• Palatin Technologies Inc. entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim International GmbH (BI) on August 14, 2025.
• The agreement focuses on researching, developing, and commercializing first-in-class melanocortin receptor-targeted peptides for retinal diseases, including diabetic retinopathy.
• Palatin assigned certain patent rights to BI and will conduct collaborative research at BI's expense for an initial two-year period, extendable by up to 6 months.
• Palatin will receive an upfront payment of $2.3 million USD (2.0 million EUR).
• Potential near-term research milestone payments could reach up to $20.9 million USD (18.0 million EUR).
• Success-based development, regulatory, and commercial milestone payments could total up to $301.6 million USD (260 million EUR).
• Palatin is also eligible for tiered royalties on net commercial sales of products, subject to reductions due to patent expiration, generic competition, and third-party intellectual property licenses.
• The agreement continues until the expiration of the applicable royalty term, unless terminated earlier by either party.
• BI has the right to terminate the agreement for any reason after a specified notice period; both parties can terminate for bankruptcy or material, uncured breach.
• A press release announcing the agreement was issued by BI and Palatin on August 18, 2025.
• Palatin's common stock was delisted from NYSE American on May 7, 2025, due to its low selling price.
• Since August 12, 2025, Palatin's common stock has traded on the OCTQB Market of the OTC Markets Group under the trading symbol PTNTD.

Sentiment

Score: 8

Explanation: Despite the recent NYSE delisting, the licensing agreement with Boehringer Ingelheim represents a significant positive development for Palatin, providing substantial potential funding and validating its core technology. The partnership with a major pharmaceutical company for a first-in-class therapy in a high-unmet-need area is a strong indicator of future potential, outweighing the negative impact of the delisting in terms of long-term strategic outlook.

Positives

• Secured a significant global research collaboration and licensing agreement with Boehringer Ingelheim, a major biopharmaceutical company.
• Potential for substantial financial inflows, including an upfront payment of $2.3 million USD, up to $20.9 million USD in near-term research milestones, and up to $301.6 million USD in success-based development, regulatory, and commercial milestones, plus tiered royalties on net sales.
• The collaboration validates Palatin's portfolio of melanocortin agonists and their potential in retinal health.
• Boehringer Ingelheim will bear the expense of the collaborative research during the initial two-year period, reducing Palatin's R&D burden.
• The partnership addresses a high unmet medical need in retinal diseases, particularly diabetic retinopathy, which is a leading cause of blindness.
• The agreement focuses on a potential first-in-class, differentiated mechanism targeting key drivers of retinal diseases: inflammation, vascular dysfunction, and neurodegeneration.

Negatives

• Palatin's common stock was delisted from NYSE American on May 7, 2025, due to its low selling price, impacting liquidity and institutional investor access.
• The company's common stock now trades on the OCTQB Market of the OTC Markets Group, which may have lower trading volumes and less visibility.
• Royalty payments are subject to reduction due to factors such as patent expiration, generic competition, and payments for third-party intellectual property.
• Boehringer Ingelheim retains the right to terminate the agreement for any reason after a specified notice period, introducing a degree of uncertainty.

Risks

• Actual results may differ materially from forward-looking statements due to various factors, including clinical trial outcomes, regulatory actions, and market acceptance.
• Boehringer Ingelheim has the right to terminate the Agreement for any reason after a specified notice period, which could impact future milestone and royalty payments.
• Either party can terminate the Agreement in the event of the other party's bankruptcy or a material, uncured breach.
• Royalty payments are subject to reduction due to patent expiration, generic competition, and payments made under certain licenses for third-party intellectual property.
• The success of the collaboration depends on the ability to fund development, successfully complete clinical trials, and obtain regulatory approvals.
• Competition from products developed by competing pharmaceutical, biopharmaceutical, and biotechnology companies could impact commercial success.

Future Outlook

The collaboration aims to research, develop, and commercialize first-in-class melanocortin receptor-targeted peptides for retinal diseases, including diabetic retinopathy, over an initial two-year period, extendable by up to six months. This partnership is expected to accelerate the research program and potentially lead to innovative therapies for patients worldwide, strengthening Boehringer Ingelheim's pipeline in eye health.

Management Comments

• "Millions of people worldwide face a progressive decline in their independence and connection to the world due to vision loss caused by complications of diabetic retinopathy, such as DME." Remko Bakker, Head of Eye Health and Research Beyond Borders at Boehringer Ingelheim.
• "Given the high treatment burden associated with DR, the potential of a melanocortin receptor agonist is a strategic fit with our pipeline focusing on addressing the three main drivers of retinal disease: inflammation, vascular dysfunction, and neurodegeneration. Importantly, this mechanistic approach may also be applicable in retinal diseases beyond DR where high unmet needs remain." Remko Bakker.
• "This collaboration with Boehringer further validates the promise of our portfolio of melanocortin agonists and the possibility of unlocking tremendous clinical and commercial potential in retinal health." Carl Spana, Palatin's President and Chief Executive Officer.
• "Boehringer's expertise in advancing innovative health care products, combined with its global commercial reach, make them the ideal strategic partner to accelerate this research program in DR and DME for the potential benefit of patients worldwide." Carl Spana.

Industry Context

Diabetic retinopathy (DR), including diabetic macular edema (DME), affects one in three people with diabetes and is the leading cause of blindness in working-age people. Patients with DME face significantly higher healthcare costs, highlighting a substantial unmet medical need for new, less burdensome treatment approaches. The collaboration's focus on melanocortin receptor agonists represents a differentiated mechanism targeting key drivers of retinal diseases (inflammation, vascular dysfunction, neurodegeneration), aligning with broader industry efforts to develop innovative therapies beyond existing anti-VEGF treatments.

Stakeholder Impact

• Shareholders: Potential for significant future revenue streams and increased company valuation due to the licensing agreement, though current trading on OTCQB may limit liquidity and investor access.
• Patients: Potential for a new, first-in-class treatment option for retinal diseases, particularly diabetic retinopathy, addressing a high unmet medical need and potentially reducing treatment burden.
• Employees: Continued employment and engagement in collaborative research activities with a major pharmaceutical partner.

Next Steps

• Palatin will conduct collaborative research with Boehringer Ingelheim for an initial two-year period, extendable by up to 6 months.
• The complete text of the Agreement will be filed as an exhibit to Palatin's Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

Key Dates

Recommendation

The licensing agreement with Boehringer Ingelheim is a transformative event for Palatin, providing significant non-dilutive funding potential (up to $324.8 million in milestones plus royalties) and validating its melanocortin receptor technology. This partnership with a global pharmaceutical leader for a first-in-class therapy targeting a large unmet medical need (diabetic retinopathy) substantially de-risks the development pathway and provides a clear path to potential commercialization. While the recent NYSE delisting is a negative for liquidity and institutional access, the fundamental value creation from this deal makes Palatin a compelling speculative buy for investors willing to accept the OTC market trading environment, given the substantial upside potential if milestones are met.

Keywords

Biopharmaceutical, Retinal Diseases, Diabetic Retinopathy, Melanocortin Receptor, Drug Development, Licensing Agreement, Boehringer Ingelheim, Palatin Technologies, Eye Health, Ophthalmology